Developed by Intersect ENT and FDA approved in December, 2017, SINUVA™ was designed as a targeted approach for treating recurrent nasal polyps in patients who have had previous ethmoid sinus surgery. (5)
Repeat surgeries and continued steroid treatment have limitations. Nasal sprays and rinses depend on consistent patient management. SINUVA™ is the innovative implant treatment that may be an alternative to additional sinus surgery and other options. (4)
How Does SINUVA™ Work? (4)
Placed during a routine office visit, SINUVA™ expands into the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyps over the course of 90 days. The implant usually cannot be felt once it’s in place.
SINUVA™ is proven to shrink nasal polyps, reduce nasal and sinus obstruction, improve a patient’s sense of smell, and reduce the need for surgery.
As it stays in the sinus, SINUVA™ continues to release medication. It gradually softens over time and can be removed 90 days after placement or earlier at the physician’s discretion.
Is SINUVA™ Safe? (4)
The safety of SINUVA™ was established by 400 patients in 2 clinical trials. In the studies, patients who received SINUVA™ experienced improvement in their impaired sense of smell, and significant reduction in nasal obstruction/congestion and severity of polyps.
The risks from SINUVA™ are similar to those associated with other endoscopic sinus procedures.